Can You Take ASCEND Blend With Tirzepatide or Semaglutide?

The products this page covers:

Prices are all-in, covering medication, physician review, refill management and shipping, with no membership fee. GLP-1 prices are "from" prices, set by dose. Pepti is cash-pay and does not bill insurance. Compounded medications are not FDA approved.

Weight lost on a GLP-1 is not all fat. In the STEP 1 body-composition substudy of semaglutide, both fat mass and lean mass fell, though fat fell by more. Strong appetite suppression also makes under-eating protein easy. That is the rationale prescribers give for adding a growth-hormone-axis product: lean tissue, alongside training and protein, not instead of them.

There is a second, narrower reason people ask about tesamorelin-containing blends: visceral fat. Tesamorelin's trials, at 1 to 2 mg daily, reported less visceral fat on CT with no change in the fat under the skin, in people with HIV and in one 12-month trial of abdominally obese adults. ASCEND delivers 0.5 mg of tesamorelin five nights a week, shared with three other peptides, which is not what those trials tested. If visceral fat is the goal, tesamorelin vs semaglutide covers that comparison directly.

What the pairing does not have is evidence that it works. No trial shows a growth hormone secretagogue preserves lean mass during GLP-1 treatment. The muscle findings for IGF-1 are in animals, and IGF-1 LR3 has essentially no published human clinical studies.

Ipamorelin acts at the receptor ghrelin uses to signal hunger, and hunger after an ASCEND dose is expected. Alongside a GLP-1 that runs against what the GLP-1 is doing. With IGF-1 LR3 in the same vial, hunger with shakiness or sweating should be treated as possible low blood sugar until shown otherwise. In rats ipamorelin also sped gastric emptying, where a GLP-1 slows it; nobody has studied the two together, and the one human trial of intravenous ipamorelin after bowel surgery did not separate from placebo.

Starting ASCEND in the same week as a GLP-1 dose step makes this table harder to use. More is in ASCEND blend side effects and GLP-1 side effects.

Both run on a 28-day refill cycle, one vial per fill. Two vials, two syringes, two sites. Your physician sets your directions after reviewing your intake, and they are printed on each vial. Dose detail is in ASCEND blend dosage.

Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.

Tirzepatide and semaglutide have a very large human evidence base in their FDA-approved forms; the compounded versions share the active ingredients, and the trial data belongs to the manufactured products. In ASCEND, tesamorelin has randomised trials at higher daily doses, CJC-1295 has small studies of a different form in healthy adults, ipamorelin has a pharmacokinetic study and one negative intravenous trial, and IGF-1 LR3 has essentially no human clinical studies. No study has tested the four together, and none has combined any of them with a GLP-1. The low blood sugar point is an inference from native IGF-1 and the analogue's design, not a measured interaction, which is why it is handled as a precaution.

On the FDA side, CJC-1295 and ipamorelin were reviewed by an advisory committee in 2024 and now sit in no 503A category, with no final determination issued; tesamorelin is the active ingredient of an approved product, prescribed off-label here; IGF-1 LR3 has never been nominated or reviewed. Compounded ASCEND is not FDA approved.

1. Complete a free online intake covering your history, every medication including insulin or any other glucose-lowering drug, cancer and family history, and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares each prescription. Lot test results are published at /quality/lab-results.
4. Each vial ships refrigerated with ice packs, ready to use, with sterile syringes and alcohol prep pads and its directions printed on the vial.
5. Start ASCEND when your GLP-1 dose is steady, not in the week of an increase. Refills run every 28 days, and your care team stays reachable.

Step by step: how to get ASCEND prescribed online and how to get tirzepatide prescribed online. The wider picture is in what peptides can you take with tirzepatide.